Novartis plans to maintain its focus on mergers and acquisitions (M&A) that target early-stage developments and near-launch products, according to CEO Vas Narasimhan. The company will prioritize deals valued under $2 billion for early-stage projects and agreements involving products expected to reach the market within five years.
This strategy reflects Novartis’ ongoing efforts to strengthen its pipeline by acquiring promising assets at various stages of development. Narasimhan outlined the approach during a statement on Wednesday, emphasizing the company’s commitment to balancing investments in both innovative early-stage research and late-stage opportunities with shorter timelines for market entry.
Newsflash | Powered by GeneOnline AI
Source: GO-AI-ne1
For any suggestion and feedback, please contact us.
Date: February 4, 2026
發佈留言